Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and ...

Can AI be used in anti-VEGF selection process and in the detection ... in retinal fluid volume quantification from repeated self-imaging with home OCT in eyes with neovascular age-related macular ...

Ocular Therapeutix (OCUL) stock rises as its Phase 3 trial for lead asset Axpaxli in wet AMD nears enrollment target. Read ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Anti-VEGF therapy is effective for neovascular age-related macular degeneration (AMD); however, there are patients who fail to respond to monotherapy alone. Angiogenesis is a complex process that ...

Aims To determine the effect of continuing anti-vascular endothelial growth factor (VEGF) injections on the progression of macular atrophy (MA) during remission of neovascular age-related macular ...

Purpose To analyse the morphological characteristics of eyes with neovascular age-related macular degeneration (AMD ... years of follow-up after initiating anti-VEGF therapy. Spectral-domain optical ...

Blurry, distorted vision is a common symptom of wet AMD (age-related macular degeneration). Your eyes may also have difficulty adjusting to changes in lighting. Wet AMD is a chronic eye condition ...